Dr. Stadler is a clinical trialist focused on developing novel therapies and biomarkers, especially for genitourinary cancer. In addition to an extensive history performing trials in kidney, bladder, and prostate cancer, he also has broad experience in leading efforts supporting clinical trial infrastructure and conduct. These include renal cancer cadre leader for the Cancer and Leukemia Group B (CALGB, now Alliance), PI for a DOD funded prostate cancer clinical trials consortium, co-PI for a Prostate Cancer SPORE, PI for the NCI funded N01 contract for early phase clinical trials, and a current role as Dean for Clinical Research
University of Chicago
Chicago, IL
Postdoctoral Fellow - Oncology
1994
University of Chicago
Chicago, IL
Fellow - Oncology
1993
Michael Reese Hospital
Chicago, IL
Resident - Internal Medicine
1991
Yale University School of Medicine
New Haven, CT
MD - Medicine
1988
University of Illinois
Urbana, IL
BS - Chemistry
1984
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer.
A phase I trial of enzalutamide plus selective glucocorticoid receptor modulator relacorilant in patients with metastatic castration resistant prostate cancer. Clin Cancer Res. 2024 Mar 27.
PMID: 38536082
Bladder-Preserving Trimodality Therapy With Capecitabine.
Bladder-Preserving Trimodality Therapy With Capecitabine. Clin Genitourin Cancer. 2024 Apr; 22(2):476-482.e1.
PMID: 38228414
Optimizing the doses of cancer drugs after usual dose finding.
Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2023 Dec 27; 17407745231213882.
PMID: 38148731
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness.
PROMISE Registry: A prostate cancer registry of outcomes and germline mutations for improved survival and treatment effectiveness. Prostate. 2024 Feb; 84(3):292-302.
PMID: 37964482
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.
Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics. Molecules. 2023 Aug 13; 28(16).
PMID: 37630292
Enrollment Barriers for Molecular Targeted Trials.
Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 06 01; 9(6):863-864.
PMID: 37022722
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.
PMID: 37182801
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial.
Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma: The CANTATA Randomized Clinical Trial. JAMA Oncol. 2022 10 01; 8(10):1411-1418.
PMID: 36048457
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer.
A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer. 2022 Dec; 20(6):575-580.
PMID: 36210299
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors.
Evaluation of Provider Preferences in First-Line Metastatic Renal Cell Carcinoma: Comparison Between Dual Immunotherapy vs. Immunotherapy/Tyrosine Kinase Inhibitors. Clin Genitourin Cancer. 2022 Dec; 20(6):510-514.
PMID: 35869002